Companies /Healthcare
West Pharmaceutical Services Inc
NYSE: WST Medical Instruments & Supplies
$417.80
▲ $1.38 (+0.33%) today
Markets closed · 5:12am ET

West Pharmaceutical Services (WST) Earnings History & Trends

EPS and revenue vs. Street estimates · SEC filings
WST vs Market · 30-day return after each reportWSTS&P 500
−10%−5%0%+5%−11.4%+1.3%Q2 25−10.8%−0.5%Q3 25−1.7%−1.5%Q4 25+2.1%+6.0%Q1 26−0.6%+3.4%Q2 26
−10%−5%0%+5%Q2 25Q3 25Q4 25Q1 26Q2 26
WST EPS Trend · estimate vs actualEstimateActual
$0.00$0.80$1.60$2.40$1.51$1.84Q2 25$1.69$1.96Q3 25$1.83$2.04Q4 25$1.68$2.13Q1 26$2.08$2.37Q2 26$2.20$2.66Q3 26
$0.00$0.80$1.60$2.40Q2 25Q4 25Q2 26
WST Revenue Trend · estimate vs actualEstimateActual
$0$300.0M$600.0M$900.0M$726.2M$766.5MQ2 25$787.7M$804.6MQ3 25$794.8M$805.0MQ4 25$779.4M$844.9MQ1 26$840.0M$872.3MQ2 26$826.5M$874.5MQ3 26
$0$300.0M$600.0M$900.0MQ2 25Q4 25Q2 26

How Often Does West Pharmaceutical Services Beat Earnings Estimates?

West Pharmaceutical Services beat EPS estimates in 6 of its last 6 reported quarters, and has beaten 6 quarters in a row.

WST quarterly earnings per share and revenue versus Street estimates
Quarter EPS · est. Surprise Revenue · est. Surprise
Q3 2026 Adjusted EPS excludes a net $54.0 million pre-tax M&A benefit (mainly a $55.7 million gain on the SmartDose 3.5mL sale to AbbVie, with a $22.4 million one-time tax cost), $6.3 million of restructuring charges, $1.8 million of other nonrecurring professional fees (legal matters, May 2026 cybersecurity incident) and amortization; GAAP diluted EPS was $3.02 $2.66 est. $2.20 +21.12% $874.5M est. $826.5M +5.80%
Q2 2026 $2.37 est. $2.08 +13.86% $872.3M est. $840.0M +3.85%
Q1 2026 $2.13 est. $1.68 +27.07% $844.9M est. $779.4M +8.41%
Q4 2025 $2.04 est. $1.83 +11.54% $805.0M est. $794.8M +1.28%
Q3 2025 $1.96 est. $1.69 +16.31% $804.6M est. $787.7M +2.15%
Q2 2025 $1.84 est. $1.51 +21.98% $766.5M est. $726.2M +5.55%

Figures from SEC filings and company reports. Not investment advice.